Literature DB >> 99030

Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.

D T Mason.   

Abstract

Digitalis and diuretics constitute conventional therapy of congestive heart failure, but systemic vasodilators offer an innovative approach in acute and chronic heart failure of decreasing increased left ventricular systolic wall tension (ventricular afterload) by reducing aortic impedance and/or by reducing cardiac venous return. Thus, vasodilators increase cardiac output (CO) by diminishing peripheral vascular resistance (PVR) and/or decrease increased left ventricular end-diastolic pressure (LVEDP) (ventricular preload) by diminishing venous tone. Concomitantly, there is reduction of myocardial oxygen demand, thereby reliably reducing angina pectoris in coronary disease, and potentially limiting infarct size and ischemia provided systemic arterial pressure remains normal. The vasodilators produce disparate modifications of cardiac function depending upon their differing alterations of preload versus impedance: nitrates principally cause venodilation (decrease LVEDP); nitroprusside, phentolamine and prazosin produce balanced arterial and venous dilation (decrease LVEDP and increase CO) provided left ventricular filling pressure is maintained at the upper limit of normal; whereas hydralazine predominantly effects arteriolar dilation (increases CO). With depressed CO plus highly increased LVEDP and increased PVR, nitrates also induce some increase of CO by reducing PVR. Combined nitroprusside and dopamine synergistically enhance CO and decrease LVEDP. Mechanical counterpulsation aids nitroprusside in acute myocardial infarction. The 30-minute venodilator action of sublingual nitroglycerin is extended for 4 to 6 hours by cutaneous nitroglycerin ointment, by sublingual and oral isosorbide dintrate, and by oral pentaerythritol tetranitrate and sustained-release nitroglycerin capsules. Ambulatory oral vasodilator therapy is provided by long-acting nitrates (relieve pulmonary congestion); hydralazine (improves fatigue); prazosin alone, combined nitrate-hydralazine combined prazosin-hydralazine (improve both dyspnea and fatigue).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 99030     DOI: 10.1016/0002-9343(78)90700-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

Review 1.  Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

Authors:  M Packer
Journal:  Drugs       Date:  1982-07       Impact factor: 9.546

2.  Mathematical model of cardiovascular mechanics for diagnostic analysis and treatment of heart failure: Part 2. Analysis of vasodilator therapy and planning of optimal drug therapy.

Authors:  H Tsuruta; T Sato; N Ikeda
Journal:  Med Biol Eng Comput       Date:  1994-01       Impact factor: 2.602

Review 3.  Vasodilators in acute circulatory failure.

Authors:  C Blakeley; J Tinker
Journal:  Intensive Care Med       Date:  1983       Impact factor: 17.440

4.  Treatment of acute left heart failure using dobutamine and intraaortic counterpulsation. Animal experiments and first clinical experiences.

Authors:  B Reichart; R Türk; E Alt; B Kemkes; E Kreuzer; J Holtz; N Franke; P Schmucker
Journal:  Intensive Care Med       Date:  1981-04       Impact factor: 17.440

5.  Hemodynamics and renal function during low frequency positive pressure ventilation with extracorporeal CO2 removal. A comparison with continuous positive pressure ventilation.

Authors:  L Gattinoni; A Agostoni; G Damia; D Cantaluppi; C Bernasconi; L Tarenzi; A Pelizzola; G P Rossi
Journal:  Intensive Care Med       Date:  1980-05       Impact factor: 17.440

6.  The effect of acute elevation of blood pressure on myocardial performance during enflurane and enflurane with nitrous oxide anaesthesia in man.

Authors:  P C Duke; M Morton; S Trosky
Journal:  Can Anaesth Soc J       Date:  1982-03

7.  Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.

Authors:  A D Struthers; R Whitesmith; J L Reid
Journal:  Br Heart J       Date:  1983-09

8.  Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.

Authors:  L B Tan; R G Murray; W A Littler
Journal:  Br Heart J       Date:  1987-08

9.  Acute haemodynamic effects of oral prazosin in severe mitral regurgitation.

Authors:  J Mehta; R L Feldman; W W Nichols; C J Pepine; C R Conti
Journal:  Br Heart J       Date:  1980-05

Review 10.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.